Whole-body 18FDG positron emission tomography in the staging of non-small cell lung cancer
| Autor: | A. Dowlati, Benoît Ghaye, Roland Hustinx, Jean-Louis Corhay, P. Paulus, Thierry Bury, Maurice Radermecker, Pierre Rigo |
|---|---|
| Rok vydání: | 1997 |
| Předmět: |
Male
Pulmonary and Respiratory Medicine Fluorine Radioisotopes medicine.medical_specialty Lung Neoplasms Sensitivity and Specificity Metastasis Fluorodeoxyglucose F18 Predictive Value of Tests Carcinoma Non-Small-Cell Lung Biopsy medicine Carcinoma Humans Prospective Studies Stage (cooking) Prospective cohort study Lung cancer Neoplasm Staging medicine.diagnostic_test business.industry Magnetic resonance imaging Middle Aged medicine.disease Magnetic Resonance Imaging Positron emission tomography Lymphatic Metastasis Female Radiology Radiopharmaceuticals Tomography X-Ray Computed Nuclear medicine business Tomography Emission-Computed |
| Zdroj: | European Respiratory Journal. 10:2529-2534 |
| ISSN: | 1399-3003 0903-1936 |
| Popis: | Despite advances in morphological imaging, some patients with lung cancer are found to have nonresectable disease at surgery or die of recurrence within yr of surgery. We performed a prospective study in 109 patients to compare the accuracy of whole-body positron emission tomography (PET) using fluorine-18 deoxyglucose (18FDG) and conventional imaging (CI) methods for the staging of non-small cell lung cancer (NSCLC). When CI or PET study suggested metastatic disease, confirmation was obtained by biopsy or follow-up information. As compared to CI, 18FDG-PET correctly changed the N stage in 22 patients (33%) and the M stage in 15 patients (14%). For the detection of distant metastases, PET study showed five false-positive sites and no false-negative cases. Currently, the accuracy of PET in the detection of M stage is 96%. Our study shows that visual interpretation of whole-body fluorine-18 deoxyglucose-positron emission tomography images can improve the diagnostic accuracy in the staging of non-small cell lung cancer. Further experience is needed to establish if metabolic imaging would be a cost-effective tool in the future management of lung cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|